How Have You Been Utilizing Idelalisb and Ibrutinib in CLL

How Have You Been Utilizing Idelalisb and Ibrutinib in CLL

ASHReport

3 years
374 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Utilizing Idelalisb and Ibrutinib in CLL at ASH 2015
Up Next Autoplay
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Kidney Cancer
25 Views
kidneycancer 22 hours
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
7 Views
UVA Cancer Center 23 hours
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
3 Views
Cancer-News 1 day
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
11 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
4 Views
CURC 2 days
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 2 days
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 2 days
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 2 days
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 2 days